Collectively, our data provide a new mechanism for tumorigenicity of ACTL6A and reveal a previously unappreciated role for FSH/ACTL6A/PGK1 axis facilitates glycolysis in ovarian cancer. The gene discussed is BRD2; the disease is ovarian cancer.